The collapse of 23andMe and its swift acquisition by Regeneron Pharmaceuticals has sent shockwaves through the tech and biotech sectors—not just for its financial implications, but for what it reveals about the fragile state of genetic data privacy. With the personal DNA of over 15 million users now in the